Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

It’s OK to Sell the News on Ocugen and Covaxin

By Chris Markoch, InvestorPlace Contributor

OCGN stock jumped when Covaxin received WHO approval. But with two major obstacles in the way of U,S. approval, you should sell the news.

7 Gene Editing Stocks Promising to Change our DNA

By Chris Markoch, InvestorPlace Contributor

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market.

Familiarity May Not Breed Contempt When It Comes to Novavax Stock

By Chris Markoch, InvestorPlace Contributor

The Novavax vaccine might indeed reduce vaccine hesitancy in the United States. If that’s true than NVAX stock may have much more upside than I previously imagined.

For GameStop Stock Investors, Perception May Be Reality That’s in the Way

By Chris Markoch, InvestorPlace Contributor

GME stock is trending lower after earnings. This is a familiar pattern; but the company's passionate base of investors may still have something to say.

It’s OK to Keep Some Chips Off the Table With Lucid Motors

By Chris Markoch, InvestorPlace Contributor

Lucid Motors has ambitious goals that may be delayed until the global chip shortage is resolved. Invest in LCID stock accordingly.

Load More